Article
Author(s):
AIDS Action Committee adds onsite specialty HIV MOMS Pharmacy to their new drop-in center.
AIDS Action Committee adds onsite specialty HIV MOMS Pharmacy to their new drop-in center.
The AIDS Action Committee, New England’s first and largest AIDS organization, announced February 22 that they will open a MOMS Pharmacy in the back of the AIDS Action Committee location in the Jamaica Plain area of Boston, Massachusetts.
MOMS Pharmacy is a specialty pharmacy that is focused exclusively on providing medications and support services to people living with HIV/AIDS. The company already has multiple locations in California, Washington, and New York.
For 20 years, MOMS has worked in the HIV/AIDS specialty pharmacy field, focusing on patient care outcomes. MOMS offers reimbursement services such as client advocacy and coordination of insurance benefits to assist their patients in accessing all of the medications prescribed by their physician at the most affordable cost. Additionally, MOMS is equipped to provide onsite counseling with a pharmacist trained in HIV/AIDS medication protocols, educational and wellness sessions, refill reminder programs, and delivery service options.
AIDS Action Committee made the decision to include MOMS’ services to their location after learning of their work with the organization Action Point by the San Francisco Department of Public Health. By working with Action Point, MOMS was instrumental in helping to cut patient hospital costs by 59% and reducing the average patient viral load by approximately 60%.
MOMS is best known for their innovative personal adherence tool, the MOMSPak, which are customized medication packages for the treatment of HIV/AIDS. The opening of the MOMS Pharmacy marks AIDS Action Committee’s attempt to promote medication adherence to their clients.
Rebecca Haag, President and CEO of AIDS Action Committee, believes having a specialty pharmacy onsite with an HIV/AIDS focus will make it easier for patients to stick to their medication regimens.
“Ultimately, this is going to lead to better health outcomes for our clients. That, in turn, reduces the spread of HIV, reduces suffering for those with HIV, and reduces health care costs,” Haag told Rainbow Times.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa